Compare InMode Ltd (INMD) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Merck & Co., Inc. — how do they compare? InMode Ltd trades at $14.22 (market cap $809.93M), while Merck & Co., Inc. trades at $146.29 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 433.7× InMode Ltd's market cap, and Merck & Co., Inc. pays a 2.39% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Merck & Co., Inc. for 98 Days on average.
| INMD | MRK | |
|---|---|---|
Market Cap | $809.93M | $351.28B |
Volume | 365,490 | 7,969,665 |
Sector | Health | Health |
52-Week High | $16.62 | $156.43 |
52-Week Low | $12.76 | $82.49 |
Typical Hold Time | 28 Days | 98 Days |
Enterprise Value | $313.27M | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $14.21, up 1.43% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 11.63, gross margins of 76.52%, and consistent profitability. Recent Q2 2026 earnings beat expectations with $95.6M revenue, while facing shareholder activism from Steel Partners' $16.75 per share acquisition offer.
Investment outlook remains cautious with analyst consensus divided (45% Buy, 55% Hold) amid cyclical industry softness. Key opportunities include international growth and new product launches like Morpheus8 Cool, while risks involve US sales declines and capital allocation concerns. The stock presents value characteristics but requires monitoring of management's strategic response to acquisition pressure.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
